Health

U.S. President Donald Trump talks to members of the press at Lehigh Valley International Airport in Allentown, Pennsylvania, U.S., August 3, 2025.Ken Cedeno | ReutersPresident Donald Trump told CNBC's "Squawk Box" on Tuesday that planned tariffs on pharmaceuticals imported into the U.S. could eventually reach up to 250%, the highest rate he has threatened so far.He said he will initially impose a "small tariff" on pharmaceuticals, but then in a year to a year and a half "maximum," he will raise that rate to 150% and then 250%.The president has repeatedly threatened and then changed course on tariff proposals, so there's no guarantee he will eventually set pharmaceutical tariffs at the 250% rate. In early July, Trump had threatened 200% tariffs on pharmaceuticals.Read more from CNBC's inter...

Linda Yaccarino attends the Milken Institute Global Conference 2025 in Beverly Hills, California, on May 5, 2025.Mike Blake | ReutersLinda Yaccarino, the former chief executive of Elon Musk's social media platform X, is pivoting into health care.The digital health company eMed Population Health on Tuesday announced it has appointed Yaccarino as its new CEO. EMed is developing a population health management platform for the blockbuster weight loss and diabetes drugs called GLP-1s, the company said. It had raised a total of $22 million as of 2022, according to PitchBook.Yaccarino, who rose to the top of NBCUniversal's global advertising business before joining X, will help eMed establish "game-changing partnerships" and navigate complex markets, the company said."The healthcare industry has ...

Hinge Health co-founders, Gabriel Mecklenburg and Daniel Perez celebrate its initial public offering at the New York Stock Exchange on May 22, 2025.NYSEShares of Hinge Health popped 6% in extended trading on Tuesday after the digital physical therapy company reported quarterly results for the first time since its debut on the New York Stock Exchange in May.Here's how the company did based on average analysts' estimates compiled by LSEG:Loss: Loss per share of $13.10. That may not compare with the 9 cents per share earnings expectedRevenue: $139 million vs. $125 million expectedRevenue at Hinge increased 55% in the second quarter from $89.8 million during the same period last year, according to a release.Hinge reported a net loss of $575.65 million, or $13.10 per share, compared to a loss o...

A combination image shows an injection pen of Zepbound, Eli Lilly's weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | ReutersA version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.For once, the Trump administration may be giving some drugmakers a reason to celebrate.The Trump administration is planning to experiment with covering costly weight loss drugs under Medicare and Medicaid, the Washington Post reported on Friday. That plan could expand access to millions of Americans with obesity who can't currently afford Novo Nordisk's Wegovy and Eli Lilly's Zepbound, blockbuster GLP-1 drugs that cost around $1,000 per month before insurance...

Packages of M&M's milk chocolate candy are stacked at a Costco Wholesale store in San Diego, California, on July 12, 2025.Kevin Carter | Getty Images News | Getty ImagesCandy maker Mars said Wednesday it has partnered with biotech company Pairwise to speed up the development of more resilient cocoa using CRISPR-based gene editing technology.The agreement gives the M&M's maker access to Pairwise's Fulcrum platform, which includes a library of plant traits, and gives Mars the ability to tailor its crops to be stronger and more sustainable.CRISPR is a gene-editing tool that makes fast and precise changes to DNA. In farming, it's used to improve crops by targeting different traits such as drought and disease resistance.The goal is to create cacao plants — the source of cacao beans, whi...

FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009. Jason Reed | ReutersA version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.A new program from the Trump administration aims to make setting up manufacturing plants in the U.S. less of a headache for the pharmaceutical industry. The Food and Drug Administration on Thursday announced a new "PreCheck" program, which will use a two-phase approach to help boost domestic drug manufacturing after it shrunk dramatically over the past two decades.  The announcement is a direct response to President Donald Trump's executive order in May calling...

Many on Wall Street expect that Novo Nordisk 's loss has been Eli Lilly 's gain, and this will be good news for the Zepbound maker's second-quarter results. Novo Nordisk's stock has cratered about 47% since the start of the year, as doubts emerged about the outlook for its GLP-1 drugs, Ozempic for diabetes and Wegovy for obesity. The company has said its business has been hurt by competition from compounding pharmacies, which are making knock-off versions of its semaglutide, the active ingredient in both brands. This prompted Novo to cut its annual forecast and oust its CEO. Lilly's business appears to be holding up much better, according to analysts. They anticipate the proof will be in the quarterly results and outlook. What's more, several analysts expect other catalysts, including next...

Eli Lilly on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs.The company raised its fiscal 2025 sales guidance to $60 billion to $62 billion, from a previous outlook of $58 billion to $61 billion on underlying strength across its business. The pharmaceutical giant also expects its adjusted fiscal 2025 earnings to come in between $21.75 and $23, up from previous guidance of $20.78 to $22.28 per share. Eli Lilly said the guidance reflects President Donald Trump's existing tariffs as of Aug. 7, but does not include his planned levies on pharmaceuticals imported into the U.S.Also on Thursday, Eli Lilly released long-awaited late-stage trial data on its experimental obesity pill, orforg...

Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial, paving the way for its entrance into the market.The pill's weight loss was 11.2% when analyzing all patients regardless of discontinuations.Shares of the company fell around 13% on Thursday. Meanwhile, shares of rival Novo Nordisk, which is also working to bring an obesity pill to the market, jumped more than 7% on Thursday.The data comes under what some Wall Street analysts were expecting for Eli Lilly's oral GLP-1, with hopes for weight loss of around 15%. Some doctors said the results appear to be comparable to, but overall slightly lower, the level of weight loss seen with Novo Nordisk's blockbuster weekly G...

Doximity at the New York Stock Exchange for its initial public offering on June 24, 2021.Source: NYSEDoximity is diving deeper into artificial intelligence, announcing on Thursday the acquisition of startup Pathway Medical for $63 million. Pathway has built an AI-powered clinical reference tool that doctors can use to ask questions about guidelines, drugs and trials. Pathway's answers are synthesized from medical literature, and Doximity said the Montreal-based startup has one of the largest structured datasets in medicine. Doximity's platform, which for years was described as LinkedIn for doctors, helps clinicians stay current on medical news, manage paperwork, find referrals and carry out telehealth appointments with patients. Through its acquisition of Pathway, Doximity hopes doctors wi...